Optimize Settings to Help Maximize Results with Omnipod® 5
Omnipod 5 real-world evidence demonstrated over
Time in range (TIR) with optimized settings1
1. Sawyer A, et al. Diabetes Technol Ther. 2026 (T1D). Data on file. 2026. RF-062026-00044 (T2D). Retrospective RWE of T1D and U.S. T2D users utilizing optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day (T1D) or ≥3 bolus/day (T2D). Optimized settings: CF x TDI ≤1500, I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL.
NEW! Omnipod 5 algorithm just got stronger with a lower 100 mg/dL Target Glucose for more time in range.2
Did you know?
53% of Omnipod 5 users not achieving glycemic targets do not frequently use the 110 mg/dL Target Glucose setting3
TIR improvement as Target Glucose setting is lowered
Real-world users increased TIR by 10 - 12% by switching from the highest setting of 150 mg/dL to 110 mg/dL Target Glucose setting with no clinically meaningful impact on time below range4.
Optimized Settings Delivered Strong TIR Across Type 1 and Type 2 Diabetes5
Real-world insights to help maximize TIR with Omnipod 5
Real-world data demonstrated the following settings can help maximize TIR1
OPTIMIZED SETTINGS
| Setting | Optimized Value | Impact | |
|---|---|---|---|
1 | Target Glucose | 110 mg/dL | Maximizes algorithm responsiveness |
2 | Insulin to Carb Ratio | ≤350 ÷ TDI | Optimize postprandial glycemia |
3 | Correction Factor | ≤1500 ÷ TDI | Improve efficacy of user-initiated corrections |
Leverage optimized settings for your Omnipod 5 patients: Small changes can lead to big improvements.
Learn more about
personalizing settings
“Practical considerations for using the Omnipod 5 Automated Insulin Delivery System:
Clinical experience from the United States and Europe”6
In Diabetes, Obesity and Metabolism Volume 27, Issue 6 Jun 2025
By: Cari Berget, et al.
The authors provide a series of clinical vignettes illustrating advanced cases related to the initiation and ongoing optimization of insulin therapy using the Omnipod 5 system, including how to personalize settings and optimize glycemic outcomes in a variety of clinical circumstances.
If you are unable to find the information you are seeking or require additional information, please contact us.
The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod® 5 System is intended for single patient, home use and requires a prescription. The Omnipod® 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, Kirsty®, and Admelog®. Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions
References:
1. Sawyer A, et al. Diabetes Technol Ther. 2026 (T1D). Data on file. 2026. RF-062026-00044 (T2D). Retrospective RWE of T1D and U.S. T2D users utilizing optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day (T1D) or ≥3 bolus/day (T2D). Optimized settings: CF x TDI ≤1500, I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL.
2. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057.
3. Insulet data on file. 2025. Retrospective analysis including 103,369 T1D users with TIR (3.9-10.0 mmol/L or 70-180 mg/dL) <70%. 54,365 (53%) did not use the 110mg/dL (6.1mmol/L) target as their average glucose target setting. RF-062025-00038
4. Forlenza G, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. Real-world data from 403 people with T1D aged 2+, and 58 people with T2D aged 18+ using the Omnipod 5 System who transitioned from the 150 mg/dL to 110 mg/dL Target Glucose. Each Target Glucose was used for a consecutive period of 14-90 days. Median time in Range (70-180 mg/dL) improved 11.8% (p<0.05), and median time <70 mg/dL +0.23% (p<0.05) for people with T1D. Median time in Range (70-180 mg/dL) improved 10.4% (p<0.05), and median time < 70 mg/dL +0.04% (non-significant) for people with T2D. Omnipod 5 results based on users with ≥75% of days with ≥220 readings available. Data on File. 05.15.25. RF-042025-00013
5. Data on file. 2026. RF-062026-00044. Retrospective RWE of US T1D users and US T2D users utilizing optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥3 bolus/day. Optimized settings: CF ≤1500/TDI (mg/dL), I:C Ratio ≤350/TDI, Average Target Glucose of 110-115 mg/dL.
6. Berget C, Annan SF, Biester T, et al. Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Diabetes Obes Metab. 2025;27(6):2909-2919. doi:10.1111/dom.16321.
INS-OHS-06-2025-00020 V5.0
References:
1. Sawyer A, et al. Diabetes Technol Ther. 2026 (T1D). Data on file. 2026. RF-062026-00044 (T2D). Retrospective RWE of T1D and U.S. T2D users utilizing optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day (T1D) or ≥3 bolus/day (T2D). Optimized settings: CF x TDI ≤1500, I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL.
2. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057.
3. Insulet data on file. 2025. Retrospective analysis including 103,369 T1D users with TIR (3.9-10.0 mmol/L or 70-180 mg/dL) <70%. 54,365 (53%) did not use the 110mg/dL (6.1mmol/L) target as their average glucose target setting. RF-062025-00038
4. Forlenza G, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. Real-world data from 403 people with T1D aged 2+, and 58 people with T2D aged 18+ using the Omnipod 5 System who transitioned from the 150 mg/dL to 110 mg/dL Target Glucose. Each Target Glucose was used for a consecutive period of 14-90 days. Median time in Range (70-180 mg/dL) improved 11.8% (p<0.05), and median time <70 mg/dL +0.23% (p<0.05) for people with T1D. Median time in Range (70-180 mg/dL) improved 10.4% (p<0.05), and median time < 70 mg/dL +0.04% (non-significant) for people with T2D. Omnipod 5 results based on users with ≥75% of days with ≥220 readings available. Data on File. 05.15.25. RF-042025-00013
5. Data on file. 2026. RF-062026-00044. Retrospective RWE of US T1D users and US T2D users utilizing optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥3 bolus/day. Optimized settings: CF ≤1500/TDI (mg/dL), I:C Ratio ≤350/TDI, Average Target Glucose of 110-115 mg/dL.
6. Berget C, Annan SF, Biester T, et al. Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Diabetes Obes Metab. 2025;27(6):2909-2919. doi:10.1111/dom.16321.
INS-OHS-06-2025-00020 V5.0